{"protocolSection":{"identificationModule":{"nctId":"NCT06325657","orgStudyIdInfo":{"id":"C3671032"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN PREGNANT PARTICIPANTS LIVING WITH HIV AND THEIR INFANTS","acronym":"MORISOT"},"statusModule":{"statusVerifiedDate":"2026-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-03-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-06-11","type":"ACTUAL"},"completionDateStruct":{"date":"2025-06-11","type":"ACTUAL"},"studyFirstSubmitDate":"2024-03-08","studyFirstSubmitQcDate":"2024-03-19","studyFirstPostDateStruct":{"date":"2024-03-22","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-05-15","resultsFirstSubmitQcDate":"2026-06-30","resultsFirstPostDateStruct":{"date":"2026-07-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-06-30","lastUpdatePostDateStruct":{"date":"2026-07-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV. These infants may have higher chances of getting sick or dying due to RSV infection. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness (airway diseases), where medical help is needed. Vaccines help your body make antibodies which help fight against diseases. The antibodies are substances your body uses to fight off an infection. The antibodies can be passed to the infant through the placenta of the mother.\n\nThe study will look at the safety, tolerability, and immune activity in mothers and their infants.\n\nThis study is seeking pregnant women who are:\n\n* Less than or equal to 49 years old and have HIV (Human immunodeficiency virus -\n* Receiving standard medical care during the pregnancy\n* Do not have syphilis (bacterial sexually transmitted disease), Hepatitis B Virus ((HBV) liver infection), Tuberculosis ((TB) bacterial lung infection).\n* Have been on stable (anti-retroviral) HIV treatment for more than or equal to 90 days.\n* agree to be present for all study visits, procedures, and blood draws.\n\nParticipants will either receive:\n\n* RSVpreF vaccine\n* A placebo. A placebo does not have any medicine it but looks just like the study vaccine.\n\nPregnant participants will be involved in the study from:\n\n* consent during their current pregnancy, and\n* for 6 months after delivery of their baby (around 10 months in total). Pregnant participants will have at least 5 planned visits in this study. Infant participants: All eligible babies born to enrolled mothers will be followed up from birth for up to 6 months. Infant participants will have at least 3 study visits, with some site visits allowed to happen via home visits or over the telephone."},"conditionsModule":{"conditions":["Respiratory Syncytial Virus"],"keywords":["Respiratory Tract Infection","HIV","Maternal","Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"This is a double-blinded, placebo-controlled study","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":681,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RSVpreF vaccine","type":"EXPERIMENTAL","description":"RSV vaccine (RSVpreF)","interventionNames":["Biological: RSVpreF vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Biological: Placebp"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF vaccine","description":"RSVpreF vaccine","armGroupLabels":["RSVpreF vaccine"]},{"type":"BIOLOGICAL","name":"Placebp","description":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination","description":"Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.","timeFrame":"From Day 1 to Day 7 after vaccination"},{"measure":"Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \\[H\\]), moderate (\\>2 times in 24 H), severe (required intravenous \\[IV\\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.","timeFrame":"From Day 1 to Day 7 after vaccination"},{"measure":"Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.","timeFrame":"From vaccination on Day 1 up to 1 month after vaccination"},{"measure":"Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)","description":"AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \\<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).","timeFrame":"From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)"},{"measure":"Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.","timeFrame":"From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)"},{"measure":"Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age","description":"AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \\<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \\<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \\[\\<=\\] 1000 g) were reported as serious AESIs.","timeFrame":"From birth up to 6 months of age"},{"measure":"Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age","description":"Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.","timeFrame":"Within 1 Month after birth"},{"measure":"Number of Infant Participants With Congenital Malformations/Anomalies at Birth","description":"Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.","timeFrame":"At birth"},{"measure":"Number of Infant Participants With Other Neonatal Problems at Birth","description":"Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.","timeFrame":"At birth"},{"measure":"Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","timeFrame":"1 minute after birth"},{"measure":"Number of Infant Participants According to APGAR Score at 5 Minutes After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","timeFrame":"5 minutes after birth"},{"measure":"Number of Infant Participants According to APGAR Score at 10 Minutes After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","timeFrame":"10 minutes after birth"},{"measure":"Number of Infant Participants According to Gestational Age (GA) at Birth","description":"GA at birth was collected as:\\>=24 to \\<28 weeks, \\>=28 to \\<34 weeks, \\>=34 to \\<37 weeks, \\>=37 to \\<42 weeks, and \\>=42 weeks.","timeFrame":"At birth"},{"measure":"Number of Infant Participants Requiring Hospitalization at Birth","description":"Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.","timeFrame":"From birth until discharge from hospitalization (up to a maximum of 72 hours)"},{"measure":"Percentage of Infant Participants With AEs From Birth to 1 Month of Age","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.","timeFrame":"From birth to 1 month of age"},{"measure":"Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.","timeFrame":"From birth to 6 months of age"},{"measure":"Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age","description":"An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.","timeFrame":"From birth to 6 months of age"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants","description":"GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.","timeFrame":"Before vaccination on Day 1 and at delivery"},{"measure":"Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants","description":"GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.","timeFrame":"Before vaccination on Day 1 to delivery"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria - Maternal Participants\n\n* Women ≤49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated singleton pregnancy who are at no known increased risk for complications.\n* Confirmed stable HIV disease.\n* Current and stable use of antiretroviral therapy(ART) for at least 90 days prior to enrolment.\n* Had a fetal anomaly ultrasound examination performed at ≥18 weeks of pregnancy with no significant fetal abnormalities observed.\n* Intention to deliver at a hospital or birthing facility where study procedures can be obtained.\n* Participant is willing to give informed consent for the participant's infant to participate in the study.\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.\n\nKey Inclusion Criteria - Infant Participants\n\n* Evidence of a signed and dated ICD, signed by the parent(s)/legal guardian(s).\n* Parent(s)/legal guardian(s) willing and able to comply with scheduled visits, investigational plan, laboratory tests, and other study procedures\n\nKey Exclusion Criteria - Maternal Participants\n\n* Prepregnancy body mass index (BMI) of \\>40 kg/m2 . If prepregnancy BMI is not available, the BMI at the time of the first obstetric visit during the current pregnancy may be used.\n* Participant with opportunistic infections or malignancy.\n* History of active chronic viral hepatitis with biochemical evidence of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values \\>5 times the upper limit of normal within 6 months before enrollment.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.\n* Current pregnancy resulting from in vitro fertilization. Participants known to have used clomiphene citrate and/or letrozole with or without intrauterine insemination (IUI) are permitted.\n* Current pregnancy complications or abnormalities at the time of consent that will increase the risk associated with the participation in and completion of the study, including but not l limited to the following:\n* Preeclampsia, eclampsia, or uncontrolled gestational hypertension.\n* Placental abnormality.\n* Polyhydramnios or oligohydramnios.\n* Significant bleeding or blood clotting disorder.\n* Endocrine disorders, including untreated hyperthyroidism or untreated hypothyroidism. This also includes disorders of glucose intolerance (eg, diabetes mellitus type 1 or 2) antedating pregnancy or occurring during pregnancy if uncontrolled at the time of consent.\n* Any signs of premature labor with the current pregnancy or having ongoing intervention (medical/surgical) in the current pregnancy to prevent preterm birth.\n* Prior pregnancy complications or abnormalities at the time of consent, based on the investigator's judgment, that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:\n* Prior preterm delivery at ≤34 weeks' gestation\n* Prior stillbirth or neonatal death\n* Previous infant with a known genetic disorder or significant congenital anomaly\n* Non-HIV-associated congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other illness requiring chronic treatment with known immunosuppressant medications.\n* Antituberculosis treatment use currently or at any time during this current pregnancy.\n\nKey Exclusion Criteria - Infant Participants\n\n• Infant who is a direct descendant (eg, child or grandchild) of the investigator site staff or sponsor and sponsor delegate employees directly involved in the conduct of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"0 Years","maximumAge":"49 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Synergy Biomed Research Institute","city":"East London","state":"Eastern Cape","zip":"5241","country":"South Africa","geoPoint":{"lat":-33.01529,"lon":27.91162}},{"facility":"Josha Research","city":"Bloemfontein","state":"Free State","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"Worthwhile Clinical Trials","city":"Benoni","state":"Gauteng","zip":"1500","country":"South Africa","geoPoint":{"lat":-26.18848,"lon":28.32078}},{"facility":"REIMED Reiger Park","city":"Boksburg","state":"Gauteng","zip":"1459","country":"South Africa","geoPoint":{"lat":-26.21197,"lon":28.25958}},{"facility":"Wits RHI","city":"Johannesburg","state":"Gauteng","zip":"2001","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)","city":"Johannesburg","state":"Gauteng","zip":"2013","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Wits VIDA Nkanyezi Research Unit","city":"Johannesburg","state":"Gauteng","zip":"2093","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Setshaba Research Centre","city":"Pretoria","state":"Gauteng","zip":"0152","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Botho Ke Bontle Health Services","city":"Pretoria","state":"Gauteng","zip":"0184","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Qhakaza Mbokodo Research Clinic","city":"Ladysmith","state":"KwaZulu-Natal","zip":"3370","country":"South Africa","geoPoint":{"lat":-28.55874,"lon":29.77896}},{"facility":"Gole Biomed Research Centre","city":"Polokwane","state":"Limpopo","zip":"0699","country":"South Africa","geoPoint":{"lat":-23.90449,"lon":29.46885}},{"facility":"MRC Unit on Child And Adolescent Health","city":"Cape Town","state":"Western Cape","zip":"7700","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Gugulethu Green Clinic","city":"Cape Town","state":"Western Cape","zip":"7750","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"FAMCRU - Worcester","city":"Worcester","state":"Western Cape","zip":"6850","country":"South Africa","geoPoint":{"lat":-33.64651,"lon":19.44852}}]},"referencesModule":{"references":[{"pmid":"41441684","type":"DERIVED","citation":"Myer L, Wasserman E, Tabasum S, Shittu E, Liu Y, Jose L, Horne E, Moraba RS, Wilhase A, Zar HJ, Hussen N, Mogashoa MS, Malahleha M, Madhi SA, Sarwar UN, Snaggs H, Erdem R, Radley D, Kalinina EV, Pahud BA, Maddalena Lino M, Anastasiou OE, Swanson KA, Anderson AS, Gurtman A, Munjal I. Safety, Tolerability, and Immunogenicity of RSVpreF Vaccine in Pregnant Individuals Living with HIV. Vaccines (Basel). 2025 Dec 1;13(12):1218. doi: 10.3390/vaccines13121218."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=C3671032"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with human immunodeficiency virus (HIV) were randomized to receive a single dose of 120 micrograms (mcg) respiratory syncytial virus stabilized prefusion F subunit vaccine (RSVpreF), intramuscularly (IM) on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"FG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"FG002","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"FG003","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"172"},{"groupId":"FG001","numSubjects":"171"},{"groupId":"FG002","numSubjects":"171"},{"groupId":"FG003","numSubjects":"167"}]},{"type":"Safety Population","comment":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Infant safety population included all infant participants who were born to vaccinated maternal participants.","achievements":[{"groupId":"FG000","numSubjects":"172"},{"groupId":"FG001","numSubjects":"170"},{"groupId":"FG002","numSubjects":"171"},{"groupId":"FG003","numSubjects":"166"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"167"},{"groupId":"FG001","numSubjects":"163"},{"groupId":"FG002","numSubjects":"165"},{"groupId":"FG003","numSubjects":"158"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"9"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Protocol deviation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Infant safety population included all infant participants who were born to vaccinated maternal participants.","groups":[{"id":"BG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"BG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"BG002","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"BG003","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"171"},{"groupId":"BG003","value":"166"},{"groupId":"BG004","value":"679"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<16 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"171"},{"groupId":"BG003","value":"166"},{"groupId":"BG004","value":"337"}]},{"title":"Between 16 and 44 years","measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"342"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"80"},{"groupId":"BG003","value":"75"},{"groupId":"BG004","value":"497"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"91"},{"groupId":"BG003","value":"91"},{"groupId":"BG004","value":"182"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"168"},{"groupId":"BG003","value":"162"},{"groupId":"BG004","value":"624"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"55"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"169"},{"groupId":"BG002","value":"170"},{"groupId":"BG003","value":"166"},{"groupId":"BG004","value":"676"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination","description":"Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\\>2.0 to 5.0 cm), moderate (\\>5.0 to 10.0 cm), severe (\\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.","populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants from one of the trial sites were excluded from analysis due to a quality event associated with inappropriate capture of reactogenicity events.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 to Day 7 after vaccination","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"166"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.4","upperLimit":"5.3"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.4","upperLimit":"5.2"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.1","upperLimit":"4.3"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.4","upperLimit":"5.3"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"0.7","upperLimit":"6.2"},{"groupId":"OG001","value":"2.4","lowerLimit":"0.7","upperLimit":"6.1"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.4"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.1","upperLimit":"4.3"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.4","upperLimit":"5.3"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"27.0","lowerLimit":"20.3","upperLimit":"34.5"},{"groupId":"OG001","value":"17.5","lowerLimit":"12.0","upperLimit":"24.1"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.9","lowerLimit":"14.9","upperLimit":"27.9"},{"groupId":"OG001","value":"11.4","lowerLimit":"7.0","upperLimit":"17.3"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"3.0","upperLimit":"11.0"},{"groupId":"OG001","value":"5.4","lowerLimit":"2.5","upperLimit":"10.0"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination","description":"Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \\[H\\]), moderate (\\>2 times in 24 H), severe (required intravenous \\[IV\\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.","populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants from one of the trial sites were excluded from analysis due to a quality event associated with inappropriate capture of reactogenicity events.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 1 to Day 7 after vaccination","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"166"}]}],"classes":[{"title":"Fever: >=38.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.0","upperLimit":"7.0"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.4","upperLimit":"5.2"}]}]},{"title":"Fever: 38.0 to 38.4 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.4","upperLimit":"5.3"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Fever: 38.5 to 38.9 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.1","upperLimit":"4.4"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Fever: 39.0 to 40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Fever: >40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"27.7","upperLimit":"42.8"},{"groupId":"OG001","value":"41.6","lowerLimit":"34.0","upperLimit":"49.5"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"20.9","lowerLimit":"14.9","upperLimit":"27.9"},{"groupId":"OG001","value":"26.5","lowerLimit":"20.0","upperLimit":"33.9"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","lowerLimit":"8.7","upperLimit":"19.7"},{"groupId":"OG001","value":"13.9","lowerLimit":"9.0","upperLimit":"20.1"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.4"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.1","upperLimit":"4.3"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"33.1","lowerLimit":"26.0","upperLimit":"40.9"},{"groupId":"OG001","value":"31.9","lowerLimit":"24.9","upperLimit":"39.6"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21.5","lowerLimit":"15.4","upperLimit":"28.6"},{"groupId":"OG001","value":"22.3","lowerLimit":"16.2","upperLimit":"29.4"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"7.2","upperLimit":"17.6"},{"groupId":"OG001","value":"8.4","lowerLimit":"4.7","upperLimit":"13.7"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.1","upperLimit":"4.3"}]}]},{"title":"Nausea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"20.2","lowerLimit":"14.4","upperLimit":"27.2"},{"groupId":"OG001","value":"17.5","lowerLimit":"12.0","upperLimit":"24.1"}]}]},{"title":"Nausea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"11.7","upperLimit":"23.9"},{"groupId":"OG001","value":"13.9","lowerLimit":"9.0","upperLimit":"20.1"}]}]},{"title":"Nausea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.0","upperLimit":"7.0"},{"groupId":"OG001","value":"3.6","lowerLimit":"1.3","upperLimit":"7.7"}]}]},{"title":"Nausea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]},{"title":"Muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"25.2","lowerLimit":"18.7","upperLimit":"32.5"},{"groupId":"OG001","value":"14.5","lowerLimit":"9.5","upperLimit":"20.7"}]}]},{"title":"Muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"11.7","upperLimit":"23.9"},{"groupId":"OG001","value":"6.6","lowerLimit":"3.4","upperLimit":"11.5"}]}]},{"title":"Muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"4.3","upperLimit":"13.3"},{"groupId":"OG001","value":"7.2","lowerLimit":"3.8","upperLimit":"12.3"}]}]},{"title":"Muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]},{"title":"Joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"11.2","upperLimit":"23.2"},{"groupId":"OG001","value":"13.3","lowerLimit":"8.5","upperLimit":"19.4"}]}]},{"title":"Joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"6.7","upperLimit":"16.9"},{"groupId":"OG001","value":"7.8","lowerLimit":"4.2","upperLimit":"13.0"}]}]},{"title":"Joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"2.6","upperLimit":"10.2"},{"groupId":"OG001","value":"5.4","lowerLimit":"2.5","upperLimit":"10.0"}]}]},{"title":"Joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]},{"title":"Vomiting: Any","categories":[{"measurements":[{"groupId":"OG000","value":"12.9","lowerLimit":"8.2","upperLimit":"19.0"},{"groupId":"OG001","value":"13.3","lowerLimit":"8.5","upperLimit":"19.4"}]}]},{"title":"Vomiting: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"9.8","lowerLimit":"5.7","upperLimit":"15.5"},{"groupId":"OG001","value":"10.2","lowerLimit":"6.1","upperLimit":"15.9"}]}]},{"title":"Vomiting: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.0","upperLimit":"7.0"},{"groupId":"OG001","value":"3.0","lowerLimit":"1.0","upperLimit":"6.9"}]}]},{"title":"Vomiting: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0.0","upperLimit":"2.2"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]},{"title":"Diarrhea: Any","categories":[{"measurements":[{"groupId":"OG000","value":"9.8","lowerLimit":"5.7","upperLimit":"15.5"},{"groupId":"OG001","value":"9.6","lowerLimit":"5.6","upperLimit":"15.2"}]}]},{"title":"Diarrhea: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"3.0","upperLimit":"11.0"},{"groupId":"OG001","value":"7.8","lowerLimit":"4.2","upperLimit":"13.0"}]}]},{"title":"Diarrhea: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"3.1","lowerLimit":"1.0","upperLimit":"7.0"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.4","upperLimit":"5.2"}]}]},{"title":"Diarrhea: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.0","upperLimit":"3.4"},{"groupId":"OG001","value":"0","lowerLimit":"0.0","upperLimit":"2.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.","populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 1 month after vaccination","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"9.6","upperLimit":"20.7"},{"groupId":"OG001","value":"24.1","lowerLimit":"17.9","upperLimit":"31.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)","description":"AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \\<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).","populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"9.1","upperLimit":"20.0"},{"groupId":"OG001","value":"13.5","lowerLimit":"8.8","upperLimit":"19.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.","populationDescription":"Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","lowerLimit":"27.8","upperLimit":"42.5"},{"groupId":"OG001","value":"33.5","lowerLimit":"26.5","upperLimit":"41.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age","description":"AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \\<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \\<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \\[\\<=\\] 1000 g) were reported as serious AESIs.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From birth up to 6 months of age","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"11.2","upperLimit":"22.8"},{"groupId":"OG001","value":"17.5","lowerLimit":"12.0","upperLimit":"24.1"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age","description":"Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 1 Month after birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants With Congenital Malformations/Anomalies at Birth","description":"Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants With Other Neonatal Problems at Birth","description":"Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"1 minute after birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"159"}]}],"classes":[{"categories":[{"title":"Score <4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]},{"title":"Score 4 to <7","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]},{"title":"Score 7 to 10","measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"147"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants According to APGAR Score at 5 Minutes After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"5 minutes after birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"}]}],"classes":[{"categories":[{"title":"Score <4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Score 4 to <7","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Score 7 to 10","measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants According to APGAR Score at 10 Minutes After Birth","description":"APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \\<7 was moderate, and \\<4 was poor.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"10 minutes after birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"64"}]}],"classes":[{"categories":[{"title":"Score <4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Score 4 to <7","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Score 7 to 10","measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"64"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants According to Gestational Age (GA) at Birth","description":"GA at birth was collected as:\\>=24 to \\<28 weeks, \\>=28 to \\<34 weeks, \\>=34 to \\<37 weeks, \\>=37 to \\<42 weeks, and \\>=42 weeks.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At birth","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"title":">=24 weeks to <28 weeks","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":">=28 weeks to <34 weeks","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]},{"title":">=34 weeks to <37 weeks","measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}]},{"title":">=37 weeks to <42 weeks","measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"147"}]},{"title":">=42 weeks","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of Infant Participants Requiring Hospitalization at Birth","description":"Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From birth until discharge from hospitalization (up to a maximum of 72 hours)","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"title":"<=72 hours","measurements":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"130"}]},{"title":"> 72 hours","measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"33"}]},{"title":"Not reported","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Infant Participants With AEs From Birth to 1 Month of Age","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From birth to 1 month of age","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","lowerLimit":"27.4","upperLimit":"42.1"},{"groupId":"OG001","value":"44.0","lowerLimit":"36.3","upperLimit":"51.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age","description":"An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From birth to 6 months of age","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","lowerLimit":"13.2","upperLimit":"25.4"},{"groupId":"OG001","value":"21.7","lowerLimit":"15.7","upperLimit":"28.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age","description":"An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.","populationDescription":"Infant safety population included all infant participants who were born to vaccinated maternal participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From birth to 6 months of age","groups":[{"id":"OG000","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age."},{"id":"OG001","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"166"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.1","upperLimit":"4.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.0","upperLimit":"3.3"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants","description":"GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.","populationDescription":"All maternal participants who were eligible, received the study intervention to which they were randomized, had blood drawn for assay testing within the specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol violations. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants from one of the trial sites were excluded from analysis due to a critical quality event.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before vaccination on Day 1 and at delivery","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"139"}]}],"classes":[{"title":"RSV A: Before vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"1649","lowerLimit":"1443.5","upperLimit":"1884.8"},{"groupId":"OG001","value":"1662","lowerLimit":"1462.8","upperLimit":"1889.4"}]}]},{"title":"RSV A: At delivery","categories":[{"measurements":[{"groupId":"OG000","value":"13192","lowerLimit":"11347.9","upperLimit":"15336.8"},{"groupId":"OG001","value":"1663","lowerLimit":"1439.6","upperLimit":"1920.8"}]}]},{"title":"RSV B: Before vaccination","categories":[{"measurements":[{"groupId":"OG000","value":"2242","lowerLimit":"1937.9","upperLimit":"2593.9"},{"groupId":"OG001","value":"2075","lowerLimit":"1795.8","upperLimit":"2397.1"}]}]},{"title":"RSV B: At delivery","categories":[{"measurements":[{"groupId":"OG000","value":"16424","lowerLimit":"13999.2","upperLimit":"19269.1"},{"groupId":"OG001","value":"2297","lowerLimit":"1996.1","upperLimit":"2643.5"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants","description":"GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.","populationDescription":"All maternal participants who were eligible, received the study intervention to which they were randomized, had blood drawn for assay testing within the specified time frame, had valid and determinate assay results for the proposed analysis, and had no major protocol violations. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. Participants from one of the trial sites were excluded from analysis due to a critical quality event.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Before vaccination on Day 1 to delivery","groups":[{"id":"OG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."},{"id":"OG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"139"}]}],"classes":[{"title":"RSV A","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"6.83","upperLimit":"9.36"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.89","upperLimit":"1.12"}]}]},{"title":"RSV B","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"6.20","upperLimit":"8.66"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.99","upperLimit":"1.24"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Maternal participants: Local reactions and systemic events: From Day 1 to Day 7 after vaccination; SAEs and AESIs: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months); Other AEs: From vaccination on Day 1 up to 1 month after vaccination; Infant participants: SAEs, AESIs and NDCMCs: From birth up to 6 months of age; Other AEs: From birth up to 1 month","description":"Local reactions and systemic events were assessed by systematic assessment; AEs by non-systematic assessment. Same event may appear as both an SAE and non-SAE. But what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another, or a participant may have experienced both SAE and non-SAE. Maternal and infant safety population was evaluated. NDCMCs were reported as both AEs and SAEs.","eventGroups":[{"id":"EG000","title":"Maternal Participants: RSVpreF","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive a single dose of 120 mcg RSVpreF, IM on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery.","deathsNumAffected":1,"deathsNumAtRisk":172,"seriousNumAffected":60,"seriousNumAtRisk":172,"otherNumAffected":103,"otherNumAtRisk":172},{"id":"EG001","title":"Maternal Participants: Placebo","description":"Study-eligible pregnant women (maternal participants) living with HIV were randomized to receive placebo (matching to RSVpreF without active vaccine) IM as a single dose on Day 1 (day of vaccination). Participants were followed up to 6 months after delivery.","deathsNumAffected":2,"deathsNumAtRisk":170,"seriousNumAffected":57,"seriousNumAtRisk":170,"otherNumAffected":115,"otherNumAtRisk":170},{"id":"EG002","title":"Infant Participants: RSVpreF","description":"Infant participants born to maternal participants living with HIV who were vaccinated with a single dose of 120 mcg RSVpreF were included. Infant participants were followed from birth up to 6 months of age.","deathsNumAffected":1,"deathsNumAtRisk":171,"seriousNumAffected":32,"seriousNumAtRisk":171,"otherNumAffected":53,"otherNumAtRisk":171},{"id":"EG003","title":"Infant Participants: Placebo","description":"Infant participants born to maternal participants living with HIV who received placebo (matching RSVpreF without active vaccine) were included. Infant participants were followed from birth up to 6 months of age.","deathsNumAffected":3,"deathsNumAtRisk":166,"seriousNumAffected":36,"seriousNumAtRisk":166,"otherNumAffected":52,"otherNumAtRisk":166}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Anaemia neonatal","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Anaemia of pregnancy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cardiac arrest neonatal","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Tachycardia foetal","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cleft lip","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Congenital haematological disorder","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Congenital hydrocephalus","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Congenital pneumonia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Foetal alcohol syndrome","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Heart disease congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Microcephaly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Polydactyly","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Pulmonary artery stenosis congenital","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Talipes","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Trisomy 13","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Trisomy 18","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Trisomy 21","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Primary hypoparathyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Retinopathy of prematurity","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Necrotising colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Amniotic cavity infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Breast abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cervicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Dysentery","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Meningitis tuberculous","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Neonatal pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Sepsis neonatal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Wound sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Bladder injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Endotracheal intubation complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"HIV test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Feeding disorder","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Hypoglycaemia neonatal","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Bone metabolism disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Encephalopathy neonatal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Intraventricular haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Arrested labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Breech presentation","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cephalo-pelvic disproportion","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":5,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Failed induction of labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Failed trial of labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"False labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal distress syndrome","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":172},{"groupId":"EG001","numAffected":22,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal growth restriction","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal hypokinesia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal macrosomia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Gestational diabetes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Gestational hypertension","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":172},{"groupId":"EG001","numAffected":4,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Haemorrhage in pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Jaundice neonatal","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":4,"numAtRisk":171},{"groupId":"EG003","numAffected":5,"numAtRisk":166}]},{"term":"Low birth weight baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":5,"numAtRisk":166}]},{"term":"Meconium in amniotic fluid","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Obstructed labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Postpartum haemorrhage","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Pre-eclampsia","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":172},{"groupId":"EG001","numAffected":8,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Premature baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":5,"numAtRisk":166}]},{"term":"Premature delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":172},{"groupId":"EG001","numAffected":3,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Premature labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Premature separation of placenta","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Preterm premature rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Prolonged labour","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Prolonged pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":4,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Prolonged rupture of membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Retained placenta or membranes","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Small for dates baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Stillbirth","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Uterine scar","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Cyanosis central","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cyanosis neonatal","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Infantile apnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Meconium aspiration syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Neonatal hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Neonatal respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Neonatal respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":3,"numAtRisk":166}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Transient tachypnoea of the newborn","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":4,"numAtRisk":166}]},{"term":"Victim of homicide","organSystem":"Social circumstances","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Anaemia of pregnancy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Thrombocytopenia neonatal","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Neonatal tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Tachycardia foetal","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Congenital syphilis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Congenital umbilical hernia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":5,"numAtRisk":166}]},{"term":"Laryngomalacia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Patent ductus arteriosus","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Tethered oral tissue","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Hyperparathyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Retinopathy of prematurity","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Developmental delay","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":163},{"groupId":"EG001","numAffected":69,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":163},{"groupId":"EG001","numAffected":3,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Diarrhoea (DIARRHEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":163},{"groupId":"EG001","numAffected":16,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Nausea (NAUSEA)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":163},{"groupId":"EG001","numAffected":29,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Tongue geographic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Vomiting (VOMITING)","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":163},{"groupId":"EG001","numAffected":22,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Body tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Pustule","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Sepsis neonatal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Toxoplasmosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":5,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Perineal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"HIV test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Herpes simplex test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Abnormal loss of weight","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Underweight","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":163},{"groupId":"EG001","numAffected":22,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Growth retardation","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Ligament pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":163},{"groupId":"EG001","numAffected":24,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":163},{"groupId":"EG001","numAffected":53,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Intraventricular haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Neonatal seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Nystagmus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal distress syndrome","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Foetal growth restriction","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Gestational hypertension","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":172},{"groupId":"EG001","numAffected":4,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Jaundice neonatal","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":6,"numAtRisk":166}]},{"term":"Large for dates baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Low birth weight baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":21,"numAtRisk":171},{"groupId":"EG003","numAffected":16,"numAtRisk":166}]},{"term":"Meconium in amniotic fluid","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Polyhydramnios","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Premature baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":12,"numAtRisk":171},{"groupId":"EG003","numAffected":8,"numAtRisk":166}]},{"term":"Premature delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":172},{"groupId":"EG001","numAffected":10,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Small for dates baby","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":3,"numAtRisk":166}]},{"term":"Umbilical granuloma","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":3,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Leukocyturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":2,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Galactorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":4,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":1,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Meconium aspiration syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Neonatal respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":5,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Transient tachypnoea of the newborn","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":3,"numAtRisk":166}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Erythema toxicum neonatorum","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":2,"numAtRisk":171},{"groupId":"EG003","numAffected":2,"numAtRisk":166}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Toxic skin eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":1,"numAtRisk":171},{"groupId":"EG003","numAffected":1,"numAtRisk":166}]},{"term":"Essential hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":172},{"groupId":"EG001","numAffected":0,"numAtRisk":170},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Injection site pain (PAIN AT INJECTION SITE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":44,"numAtRisk":163},{"groupId":"EG001","numAffected":29,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":163},{"groupId":"EG001","numAffected":4,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]},{"term":"Erythema (REDNESS)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":163},{"groupId":"EG001","numAffected":3,"numAtRisk":166},{"groupId":"EG002","numAffected":0,"numAtRisk":171},{"groupId":"EG003","numAffected":0,"numAtRisk":166}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov.Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-08-24","uploadDate":"2026-05-15T12:28","filename":"Prot_000.pdf","size":845227},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-11-21","uploadDate":"2026-05-15T12:28","filename":"SAP_001.pdf","size":380298}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-06-11","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D012141","term":"Respiratory Tract Infections"}],"ancestors":[{"id":"D007239","term":"Infections"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}